Lead Product(s) : FCX-013,Veledimex
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The open label, single cohort Phase 1/2 clinical trial is evaluating the safety of FCX-013 as its primary objective. Secondary objectives include assessments of fibrosis at targeted sclerotic lesions at various time points through 26 weeks post-administr...
Brand Name : FCX-013
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 15, 2020
Lead Product(s) : FCX-013,Veledimex
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?